Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. An interesting case of chronic myeloid leukemia with twists and turns.Hematology, transfusion and cell therapy · 2024
   Article
2. The Impact of Cytogenetic Aberrations in the Clonal Evolution of Chronic Myeloid Leukemia: A Single-Center Experience Among 450 Turkish Patients (Cohort Study)Turkish journal of haematology : official journal of Turkish Society of Haematology · 2022
   Article
3. [Philadelphia chromosome-negative myeloid neoplasms in patients with Philadelphia chromosome-positive chronic myeloid leukemia during tyrosine kinase inhibtor-therapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019
   Article
4. A genomic analysis of Philadelphia chromosome-negative AML arising in patients with CML.Blood cancer journal · 2016
   Article
5. Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report.Clinical case reports · 2016
   Article
6. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.Journal of hematology & oncology · 2015
   Article
7. Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib.Leukemia · 2012
   Article
8. Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity.Cancer research and treatment · 2010
   Article
9. t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia.International journal of hematology · 2009
   Article
10. Successful application of a direct detection slide-based sequential phenotype/genotype assay using archived bone marrow smears and paraffin embedded tissue sections.The Journal of molecular diagnostics : JMD · 2007
    Article
11. [Hematological side effects of tyrosine kinase inhibition using imatinib].Der Pathologe · 2006
    Article
12. Induction of centrosome and chromosome aberrations by imatinib in vitro.Leukemia · 2005
    Article

Corrections and comments

• Comment on
  Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.2004

Authors and funding

7 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as